320 related articles for article (PubMed ID: 22166891)
1. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
Yamaori S; Koeda K; Kushihara M; Hada Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2012; 27(3):294-300. PubMed ID: 22166891
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
3. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
Yamaori S; Kushihara M; Yamamoto I; Watanabe K
Biochem Pharmacol; 2010 Jun; 79(11):1691-8. PubMed ID: 20117100
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
Drug Metab Dispos; 2011 Nov; 39(11):2049-56. PubMed ID: 21821735
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.
Watanabe K; Yamaori S; Funahashi T; Kimura T; Yamamoto I
Life Sci; 2007 Mar; 80(15):1415-9. PubMed ID: 17303175
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.
Yamaori S; Takami K; Shiozawa A; Sakuyama K; Matsuzawa N; Ohmori S
Biol Pharm Bull; 2015; 38(3):441-7. PubMed ID: 25757926
[TBL] [Abstract][Full Text] [Related]
8. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.
Jiang R; Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2013; 28(4):332-8. PubMed ID: 23318708
[TBL] [Abstract][Full Text] [Related]
10. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
Anderson GD; Chan LN
Clin Pharmacokinet; 2016 Nov; 55(11):1353-1368. PubMed ID: 27106177
[TBL] [Abstract][Full Text] [Related]
14. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
15. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
Qian Y; Wang X; Markowitz JS
Drug Metab Dispos; 2019 May; 47(5):465-472. PubMed ID: 30833288
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes.
Wang Z; Sun W; Huang CK; Wang L; Xia MM; Cui X; Hu GX; Wang ZS
Drug Dev Ind Pharm; 2015 Apr; 41(4):613-6. PubMed ID: 24517573
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
